Esperion stocks plummet from dispute over milestone payments

Esperion believes it is entitled to $300 million in milestone payments after a study showed NEXLETOL reduced certain major adverse cardiovascular events by as much as 15 percent and the risk of heart attack by 23 percent.

Related Keywords

Switzerland ,Daiicho Sankyo Europe ,Daiichi Sankyo Europe Gmb ,Roger Newton ,Daiicho Sankyo ,Exchange Commission ,Pfizer Inc ,Ann Esperion Therapeutics Inc ,Nasdaq ,Ann Arbor Based Esperion Therapeutics ,Daiichi Sankyo Europe Gmbh ,European Economic Area ,